Abstract 152P
Background
Neoadjuvant chemoradiotherapy (nCRT) is the standard initial treatment for locally advanced rectal cancer (LARC) to reduce tumor size before surgery. Although some patients achieve complete pathological response and become eligible for organ-preserving strategies, predicting nCRT response remains challenging. The intratumoral genetic heterogeneity (ITGH) has emerged as a potential biomarker in LARC patients. Tumor-infiltrating lymphocytes (TILs) enriched with cytotoxic CD8+ T-cells indicate better prognosis and treatment response. An immunohistochemistry-based score, estimating CD3+ and CD8+ enrichment in LARC TILs, is proposed as a predictive test. Elements from anti-tumoral immune response could serve as potential predictive biomarkers.
Methods
We analyzed 80 primary LARC tumors (18 responders, nCRT-R, versus nonresponders 62, nCRT-NR) through WXS and TCRseq. We evaluated nCRT response, tumor mutation burden (TMB), neoantigen load (NAL), HLA polymorphism, somatic mutation, TCR diversity/clonality, ITGH levels, and DNA mismatch repair deficiency.
Results
We identified six significantly mutated genes (KRAS, APC, TP53, FBXW7, ARID1A, SLITRK6) (p<0.05; FDR<=0.1). Somatic mutations in driver genes, 23 dMMR genes, and COSMIC somatic signatures S6, S15, S20, or S26 did not show any association with nCRT response (p>0.5; Fisher Test). We measured ITGH through MATH score, but no significant difference between nCRT-R and NR (p=0.8; Wilcoxon test) was observed. TMB and NAL were significantly higher in nCRT-NR (p<0.05). HLA somatic mutation did not have a significant impact on antigen presentation and treatment response (8 mutations in 8 patients; Pearson Chi-squared, p=0.76). HLA polymorphism was not relevant (Pearson Chi-squared, p=0.64). Finally, nCRT response was not associated with TCR Shannon diversity or clonality (Wilcoxon test, p=0.25 and p=0.48, respectively); however, we could not quantify CD8+ T-cells.
Conclusions
Gene driver signature, ITGH, or dMMR mutations/signatures were not predictive biomarkers of nCRT response; however, preliminary findings suggest a subset of highly immunogenic nCRT-NR LARCs patients could benefit from immunotherapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
R. Perez.
Funding
FAPESP: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract